Nasdaq Logs 12th Consecutive Daily Gain, Longest Winning Streak Since July 2009

• PepsiCo reported better-than-expected quarterly results on April 16, 2026, with shares rising 2.3% as customers bought more snacks. • Price cuts on Lay’s, Doritos, Cheetos, and Tostitos chips announced in February helped regain demand from price-sensitive consumers. • The earnings contribute to broader corporate profit growth exceeding analyst forecasts amid market optimism.

• Brent crude oil settled 4.7% higher at $99.39 per barrel on April 16 amid caution over Iran war. • Prices have risen from $70 pre-war to peaks near $119 due to Strait of Hormuz disruptions. • The climb tempers market optimism, highlighting persistent energy supply risks.

• IMF lowered its 2026 global growth forecast to 3.1% from 3.3% due to US-Iran conflict impacts. • The cut assumes contained conflict with 19% energy price rise, but escalation could drop growth to 2%. • 2027 outlook held at 3.2%, with effects expected to ease by mid-2026.

• The S&P 500 rose 0.8% to close above 7,000 points for the first time, while the Nasdaq Composite surged 1.6% to a record high, driven by gains in technology and software stocks and optimism over potential U.S.-Iran peace talks. • Bank of America posted a 17% rise in quarterly profit from strong trading and investment banking fee rebounds, while Morgan Stanley reported a near 30% profit jump supported by record equities trading revenue and improved dealmaking activity. • Stock index futures edged higher after-hours, with S&P 500 Futures up 0.2% to 7,070.75 points and Nasdaq 100 Futures rising 0.3% to 26,440.75 points, reflecting continued market momentum.

• The US500 index rose to 6970 points on April 15, 2026, gaining 0.04% from the previous trading session. • Amazon led gainers with a 2.55% increase, followed by Nvidia at 1.54% and Microsoft at 1.49%, while Chevron fell 2.15%. • Over the past month, the index has climbed 4.03% and is up 29.14% compared to the same period last year, according to contract-for-difference tracking.

• The U.S. Department of the Treasury announced sanctions against cartel-linked casinos and key associates operating on the U.S.-Mexico border on April 14, 2026. • The action represents a continued enforcement effort targeting financial networks connected to organized crime along the southwestern border. • The sanctions highlight the Treasury's commitment to disrupting illicit financial flows and money laundering operations tied to criminal organizations.

• The 10-year U.S. Treasury yield declined following the latest inflation report on April 10, 2026, easing from recent levels. • Equity futures pointed higher as markets opened, buoyed by the Treasury movement and broader optimism. • This reaction comes amid mixed Wall Street close and anticipation of U.S.-Iran diplomatic talks, influencing bond and stock positioning.

• Wall Street stocks closed mixed on Friday, April 10, 2026, with S&P 500 down 0.1% at 6,816.89, Dow dropping 0.6% to 47,916.47, and Nasdaq up 0.4% to 22,902.90 amid anticipation of U.S.-Iran talks post-ceasefire. • Healthcare stocks led declines with Eli Lilly falling 1.8% and Johnson & Johnson down 1.3%, offset by tech gains including Nvidia up 3% and Broadcom rising 5.3%. • Oil prices slipped while major indexes recovered most March losses from Iran conflict, now just 2.3% below S&P 500's January all-time high, though volatility persists on war news.

• The 10-year U.S. Treasury yield climbed to 4.52% Thursday following stronger-than-anticipated producer price inflation data released by the Labor Department, pushing expectations for prolonged higher rates. • Market participants reassessed bets on future rate cuts after Fed speakers emphasized the need for additional months of restrictive policy to bring inflation back toward target levels. • The yield curve steepened significantly, with the 2-year-10-year spread widening to 87 basis points, reflecting growing uncertainty about the timing and magnitude of eventual rate cuts.

• Pfizer and Merck announced the end of merger discussions Thursday after two months of negotiations, citing differing strategic visions and regulatory complexities that would have prolonged deal closure beyond acceptable timelines. • Combined company valuations, patent portfolios, and integration challenges proved insurmountable, with sources indicating antitrust concerns from the Department of Justice would have required substantial asset divestitures. • Both pharmaceutical giants pledged to pursue independent research and development pipelines, with Pfizer increasing R&D spending by 8% and Merck announcing targeted acquisitions in oncology and immunology sectors.

• Amazon posted stronger-than-expected Q1 2026 earnings Wednesday, with net income reaching $8.3 billion and revenue climbing 18% year-over-year to $147 billion, driven by robust AWS cloud services demand. • AWS revenue grew 22% annually to $28.4 billion, outpacing analyst expectations and demonstrating the resilience of enterprise cloud spending despite macroeconomic uncertainties. • Management raised full-year 2026 revenue guidance to $625 billion, representing 14% growth, citing continued momentum in cloud computing and advertising as key tailwinds for sustained profitability.